XtalPi (HKG:2228) expects to report a net loss attributable to shareholders of 215 million yuan to 275 million yuan for the first half of 2026, compared with a net profit of 82.8 million yuan a year earlier.
The company expects revenue of 380 million yuan to 400 million yuan, down from 517.1 million yuan a year earlier, primarily due to the absence of a $51 million upfront payment from a major pipeline licensing project recognized in the prior-year period, according to a Hong Kong bourse filing.
The pharma research firm also cited a more than 50% increase in research and development spending driven by continued investment in autonomous laboratories, agentic systems and drug development programs.
The company is expected to report interim results by the end of August.